CMPX vs NDAQ · $367.4M cap vs P/E 41, rev $8.26B
Compass Therapeutics Inc. (CMPX) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Compass Therapeutics Inc. (CMPX) is a biotechnology company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
CMPX does not have a complete income-statement cache yet.
Latest reported NDAQ revenue for 2025-12-31 was $8.26B. Net income was $1.79B. Revenue was up 11.6% from 2024-12-31 to 2025-12-31. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
CMPX currently screens at market cap $367.4M. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the CMPX and NDAQ stock pages for the full models.
Not investment advice.